All posts by: Michael Zand

About Michael Zand

Terminal cancer patients in complete remission after one gene therapy treatment – Telegraph.co.uk

Continue reading

2017-02-28 NEWS

Telegraph.co.uk

Terminal cancer patients in complete remission after one gene therapy treatment
Telegraph.co.uk
A groundbreaking gene therapy treatment which boosts a patient’s own immune cells has been shown to clear disease from one third of terminal patients. US pharmaceutical company Kite Pharma released results from the first six months of its trial of the
Gene Therapy Shows Promise for Aggressive LymphomaEveryday Health (blog)
New gene therapy ‘shrinks tumours like ice cubes’The Times (subscription)
Gene therapy extraordinary at fighting blood cancerNew Zealand Herald
Mirror.co.uk –Kite Pharma, Inc. | Investor Relations
all 215 news articles »
Continue reading

2017-02-28 NEWS

Telegraph.co.uk

Terminal cancer patients in complete remission after one gene therapy treatment
Telegraph.co.uk
A groundbreaking gene therapy treatment which boosts a patient’s own immune cells has been shown to clear disease from one third of terminal patients. US pharmaceutical company Kite Pharma released results from the first six months of its trial of the
Gene Therapy Shows Promise for Aggressive LymphomaEveryday Health (blog)
New gene therapy ‘shrinks tumours like ice cubes’The Times (subscription)
Gene therapy extraordinary at fighting blood cancerNew Zealand Herald
Mirror.co.uk
all 209 news articles »
Continue reading

2017-02-28 NEWS

Xconomy

With Eye On FDA, Kite Says CART For Lymphoma Holds Up After 6 Months
Xconomy
The patients were treated with a single dose of their own T cells and no other follow-up treatments, according to Kite officials. In CART cell therapy, a patients’ T cells are extracted and genetically modified outside the body to become more
Kite’s CART cancer therapy shows strong results as company races to win FDA approvalSTAT
Kite Pharma CART Cancer Therapy Shows Strong, Durable Effect in Lymphoma PatientsTheStreet.com
Kite’s shares fly high after cancer drug clears main study goalCNBC
Telegraph.co.uk –Endpoints News
all 60 news articles »
Continue reading

2017-02-28 NEWS

Single infusion of anti-CD19 CAR T-cells confers high response rate in aggressive non-Hodgkin lymphoma
Healio
The ZUMA-1 trial designed to evaluate axicabtagene ciloleucel in patients with chemorefractory aggressive B-cell non-Hodgkin lymphoma met its primary endpoint of overall response rate, according to the drug’s manufacturer.

and more »

Continue reading

2017-02-28 NEWS

Medscape

Stem Cell Transplantation May Decrease MS-Related Fatigue
Medscape
ORLANDO — Along with decreasing inflammatory activity in patients with severe multiple sclerosis (MS), immunoablation and autologous hematopoietic stemcell transplantation (aHSCT) may reduce MS-related fatigue, new research suggests.

Continue reading

2017-02-28 NEWS

Good4Utah

How to Find the Right Stem Cell Clinic
Good4Utah
Dr. Khan from Wasatch Pain Solutions explained which stem cell clinic you should choose for treatment. Dr Khan is the only Regenexx provider in Utah and he performs the most scientifically advanced stem cell procedures for spine and orthopedic conditions.
MHRA Unveils ‘Regulatory Ready’ Stem Cell LinesRegulatory Focus
Stem Cell Therapy Market Worth 145.8 Million USD by 2021Yahoo Finance
International Stem Cell Corporation Announces Third Patient with Parkinson’s Disease in Phase I Clinical TrialP&T Community
thepaper24-7.com –Baltimore Sun (blog) –Medgadget (blog)
all 18 news articles »